Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2014 Topline results were reported in an Athersys media release. 16-Week follow up results, including biomarker analyses, will be reported at a later date.
- 28 Apr 2014 Primary endpoint 'Mayo-score (rectal bleeding)' has not been met.